Camrelizumab Combined With Apatinib Etoposide and Cisplatin Treat Small-cell Lung Cancer.

  • participants needed
  • sponsor
    Fuzhou General Hospital
Updated on 29 May 2022


Small cell lung cancer is a highly malignant tumor, and its first-line treatment has not broken through platinum-containing dual-drug chemotherapy in the past 30 years. Because small cell lung cancer has the characteristics of easy resistance after first-line chemotherapy, increased difficulty in treatment after resistance, and poor efficacy of second-line treatment, how to formulate a plan that can control tumor progression to the greatest extent has become a hot issue in recent research. Recently, immunotherapy and targeted therapy have made breakthrough progress in small cell lung cancer, but its efficacy still needs to be further improved. As immune combined chemotherapy combined with targeted therapy first achieved good results in other tumors, this study aims to explore a longer disease-free survival time and higher overall survival rate of patients with small cell lung cancer through immunotherapy combined with targeted therapy combined with chemotherapy. Program to bring new hope to patients. At the same time, this study will evaluate the safety of the program, explore the prognostic indicators that may exist in the treatment, and provide new inspiration for subsequent patient selection.

Condition Pulmonary Disease, Lung Disease, Lung Neoplasm, Lung Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer, Lung Cancer, Lung Disease, lung tumor, sclc, small cell carcinoma, small cell carcinoma of the lung, PD-1 Inhibitors, PD-1 Inhibitors
Treatment Camrelizumab combined with Apatinib, Etoposide and Cisplatin
Clinical Study IdentifierNCT04490421
SponsorFuzhou General Hospital
Last Modified on29 May 2022

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note